Double cutoff strategies for plasma pTau217 to predict Tau PET positivity across multiple assay platforms: Tau-enriched and Tau-scarce cohorts for cost-effective clinical use.
Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
22 authors.
Heekyoung Kang *Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.ORCID 0000-0003-0287-6818
Yuna Gu *Alzheimer's Disease Convergence Research Center, Samsung Medical Center, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.ORCID 0009-0007-3200-3977
Jungah LeeAlzheimer's Disease Convergence Research Center, Samsung Medical Center, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.ORCID 0000-0003-4989-9670
Soyeon YoonDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Medicinaregatan 3, 413 90, Göteborg, 40530, Sweden.ORCID 0000-0003-3930-4354
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Medicinaregatan 3, 413 90, Göteborg, 40530, Sweden.ORCID 0000-0002-1890-4193
Fernando Gonzalez-OrtizDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Medicinaregatan 3, 413 90, Göteborg, 40530, Sweden.ORCID 0000-0001-7897-9456
Nicholas J AshtonDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Medicinaregatan 3, 413 90, Göteborg, 40530, Sweden.ORCID 0000-0002-3579-8804
Theresa A DayEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.ORCID 0009-0008-7321-6183
Michael W WeinerDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94143, USA.ORCID 0000-0002-0144-1954
Daeun ShinDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.ORCID 0000-0003-4834-1026
Sohyun YimDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.ORCID 0000-0002-9357-768X
Seonghyeon KimDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.ORCID 0009-0006-3288-851X
Hee Kyung ParkDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.ORCID 0000-0001-6339-0059
Min Young ChunDepartment of Neurology, Yonsei University College of Medicine, 145-1, Jayang-ro, Gwangjin-gu, Seoul, 05025, Republic of Korea.ORCID 0000-0003-3731-6132
Eun Hye LeeDepartment of Radiology and Imaging Sciences, Indiana University School of Medicine, 355 W 16th St, Indianapolis, IN, 46202, USA.ORCID 0000-0002-4206-6214
Jun Pyo KimDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.ORCID 0000-0003-4376-3107
Hee Jin KimDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.ORCID 0000-0002-3186-9441
Duk L NaDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.ORCID 0000-0002-0098-7592
Hyemin JangDepartment of Neurology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic ro 43 gil, Songpa gu, Seoul, 05505, Republic of Korea.ORCID 0000-0003-3152-1274
Sang Won SeoDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea. sw72.seo@samsung.com.ORCID 0000-0002-8747-0122
ADNI and K-ROAD study group
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
backgroundWe aimed to evaluate whether double cutoff strategies for plasma pTau217 across multiple assay platforms improve tau PET positivity prediction compared with single cutoffs and support cost-effective clinical use.
methodsWe analyzed two cohorts: K-ROAD (n = 120; tau-enriched) and NA-ADNI (n = 280; tau-scarce). Tau PET positivity was defined within the temporal meta-ROI as SUVR > mean + 2 SD of Aβ-negative CU. Single and double cutoffs were compared for accuracy and misclassification-related costs.
resultsSingle cutoffs showed good accuracy across most assays (AUCs > 0.80), except for C2N ratio. Double cutoffs modestly improved accuracy but expanded intermediate groups, in the tau-scarce cohort. Cost analyses revealed assay- and cohort-specific effects, with reductions in most settings but increases for Lilly-MSD and Janssen-Simoa.
conclusionDouble cutoff strategies should be applied with attention to assay platform and cohort context. Accuracy gains were modest, but clinical utility lies in reducing misclassification costs and guiding confirmatory PET use.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Double cutoff strategies for plasma pTau217 to predict Tau PET positivity across multiple assay platforms: Tau-enriched and Tau-scarce cohorts for cost-effective clinical use. · full record | Socratic